Published in Chest on April 23, 2010
Effects of extra-fine inhaled and oral corticosteroids on alveolar nitric oxide in COPD. Lung (2012) 0.79
Advantage of impulse oscillometry over spirometry to diagnose chronic obstructive pulmonary disease and monitor pulmonary responses to bronchodilators: An observational study. SAGE Open Med (2015) 0.78
Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD. Lung (2016) 0.77
Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of add-on therapy. Br J Clin Pharmacol (2013) 0.77
Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma. Am J Respir Crit Care Med (2013) 3.61
Respiratory symptoms, pulmonary function, and markers of inflammation among bar workers before and after a legislative ban on smoking in public places. JAMA (2006) 3.54
Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax (2010) 3.30
Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ (2011) 2.88
Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ (2013) 2.43
The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med (2014) 2.18
Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J Allergy Clin Immunol (2009) 1.61
Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. Ann Allergy Asthma Immunol (2003) 1.60
Does body mass index influence responsiveness to inhaled corticosteroids in persistent asthma? Ann Allergy Asthma Immunol (2012) 1.46
Fluticasone/Salmeterol combination confers benefits in people with asthma who smoke. Chest (2011) 1.44
The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol (2004) 1.38
Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med (2004) 1.36
A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med (2006) 1.34
Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy Clin Immunol (2006) 1.21
Long-acting beta2-agonists in asthma: not so SMART? Drug Saf (2006) 1.20
Pharmacokinetic and pharmacodynamic comparison of hydrofluoroalkane and chlorofluorocarbon formulations of budesonide. Br J Clin Pharmacol (2011) 1.15
Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med (2002) 1.11
Assessment of small-airways disease using alveolar nitric oxide and impulse oscillometry in asthma and COPD. Lung (2010) 1.09
Portable exhaled nitric oxide measurement: Comparison with the "gold standard" technique. Chest (2007) 1.09
Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet (2005) 1.06
Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer. Br J Clin Pharmacol (2010) 1.05
Explaining differential effects of tiotropium on mortality in COPD. Thorax (2013) 1.04
Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin Pharmacol (2003) 1.02
Statins in community acquired pneumonia: Evidence from experimental and clinical studies. Respir Med (2010) 1.01
Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med (2011) 0.99
Symptoms, spirometry, exhaled nitric oxide, and asthma exacerbations in clinical practice. Ann Allergy Asthma Immunol (2008) 0.98
Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. J Antimicrob Chemother (2010) 0.96
A comparison of 2 extrafine hydrofluoroalkane-134a-beclomethasone formulations on methacholine hyperresponsiveness. Ann Allergy Asthma Immunol (2006) 0.96
Cancer Screening in Unprovoked Venous Thromboembolism. N Engl J Med (2015) 0.92
Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype. Br J Clin Pharmacol (2003) 0.92
Prescribing of β-adrenoceptor antagonists in asthma: an observational study. Thorax (2011) 0.92
Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone. J Allergy Clin Immunol (2002) 0.90
Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest (2005) 0.89
Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. Br J Clin Pharmacol (2003) 0.88
Peak inspiratory flow rate is more sensitive than acoustic rhinometry or rhinomanometry in detecting corticosteroid response with nasal histamine challenge. Rhinology (2003) 0.87
A multidisciplinary intervention to reduce antibiotic duration in lower respiratory tract infections. J Antimicrob Chemother (2013) 0.86
Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate. Chest (2002) 0.86
A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics. Br J Clin Pharmacol (2003) 0.86
Effects of hydrofluoroalkane formulations of ciclesonide 400 microg once daily vs fluticasone 250 microg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br J Clin Pharmacol (2004) 0.86
Left ventricular hypertrophy in COPD without hypoxemia: the elephant in the room? Chest (2013) 0.85
Respirable dose delivery of fluticasone propionate from a small valved holding chamber, a compact breath actuated integrated vortex device and a metered dose inhaler. Br J Clin Pharmacol (2008) 0.85
Effects of intravenous and oral β-blockade in persistent asthmatics controlled on inhaled corticosteroids. Heart (2013) 0.85
In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhaler. Br J Clin Pharmacol (2009) 0.85
Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. J Allergy Clin Immunol (2002) 0.85
A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination. Pulm Pharmacol Ther (2009) 0.84
Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function. Ann Allergy Asthma Immunol (2004) 0.84
Inflammation, glucocorticoids and risk of cardiovascular disease. Nat Clin Pract Rheumatol (2008) 0.84
Determinants of airway hyperresponsiveness in mild asthma. Ann Allergy Asthma Immunol (2003) 0.83
Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. Br J Clin Pharmacol (2003) 0.83
Effects of hydrocortisone on acute β-adrenoceptor blocker and histamine induced bronchoconstriction. Br J Clin Pharmacol (2012) 0.83
Sensitivity of impulse oscillometry and spirometry in beta-blocker induced bronchoconstriction and beta-agonist bronchodilatation in asthma. Ann Allergy Asthma Immunol (2012) 0.83
Elevated levels of natriuretic peptides in patients with pulmonary thromboembolism. Respir Med (2005) 0.83
Fluorophore:dendrimer ratio impacts cellular uptake and intracellular fluorescence lifetime. Bioconjug Chem (2015) 0.82
Bronchoprotective effects of leukotriene receptor antagonists in asthma: a meta-analysis. Chest (2002) 0.82
Comparative cutoff points for adenosine monophosphate and methacholine challenge testing. Ann Allergy Asthma Immunol (2004) 0.82
Acute systemic effects of inhaled salbutamol in asthmatic subjects expressing common homozygous beta2-adrenoceptor haplotypes at positions 16 and 27. Br J Clin Pharmacol (2004) 0.82
Influence of β(2)-adrenergic receptor polymorphism on methacholine hyperresponsiveness in asthmatic patients. Ann Allergy Asthma Immunol (2013) 0.82
Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma. J Allergy Clin Immunol (2003) 0.82
Relationship of skin-prick reactivity to aeroallergens and hyperresponsiveness to challenges with methacholine and adenosine monophosphate. Allergy (2003) 0.82
Removing nasal valve obstruction in peak nasal inspiratory flow measurement. Ann Allergy Asthma Immunol (2007) 0.81
Polyplex-induced cytosolic nuclease activation leads to differential transgene expression. Mol Pharm (2013) 0.81
Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. Br J Clin Pharmacol (2003) 0.81
Impact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: a real-life retrospective cohort study. Lung (2014) 0.80
Comparison of bronchodilator response in patients with asthma and healthy subjects using spirometry and oscillometry. Ann Allergy Asthma Immunol (2011) 0.80
Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol (2004) 0.80
Relationship of mannitol challenge to methacholine challenge and inflammatory markers in persistent asthmatics receiving inhaled corticosteroids. Lung (2012) 0.80
Effect of aspirin on airway inflammation and pulmonary function in patients with persistent asthma. J Allergy Clin Immunol (2008) 0.80
Effects of extra-fine inhaled and oral corticosteroids on alveolar nitric oxide in COPD. Lung (2012) 0.79
Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. Br J Clin Pharmacol (2004) 0.79
The skin vasoconstrictor assay does not correlate significantly to airway or systemic responsiveness to inhaled budesonide in asthmatic patients. Eur J Clin Pharmacol (2003) 0.79
Polyplex exposure inhibits cell cycle, increases inflammatory response, and can cause protein expression without cell division. Mol Pharm (2013) 0.79
Are we overlooking persistent small airways dysfunction in community-managed asthma? Ann Allergy Asthma Immunol (2012) 0.79
Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial. Chest (2012) 0.78
The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis. Br J Clin Pharmacol (2003) 0.78
Short-term repeatability and correlates of laboratory measures of nasal function in patients with seasonal allergic rhinitis. Rhinology (2002) 0.78
Relationship between fractional exhaled nitric oxide and nasal nitric oxide in airways disease. Ann Allergy Asthma Immunol (2010) 0.78
An evaluation of short-term corticosteroid response in perennial allergic rhinitis using histamine and adenosine monophosphate nasal challenge. Br J Clin Pharmacol (2003) 0.78
Relationships between airway hyperresponsiveness, inflammation, and calibre in asthma. Lung (2011) 0.78
5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. Eur J Clin Pharmacol (2002) 0.78
A randomized primary care trial of steroid titration against mannitol in persistent asthma: STAMINA trial. Chest (2011) 0.78
Reproducibility of response to nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Ann Allergy Asthma Immunol (2004) 0.78
Decongestant effects of nasal xylometazoline and mometasone furoate in persistent allergic rhinitis. Rhinology (2005) 0.78
Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. Br J Clin Pharmacol (2007) 0.77
Lower thresholds for bronchial challenge testing. Allergy (2004) 0.77
Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. Ann Allergy Asthma Immunol (2005) 0.77
Pharmacological management--inhaled treatment. BMJ (2006) 0.77
Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of add-on therapy. Br J Clin Pharmacol (2013) 0.77
A proof-of-concept study to evaluate the antiinflammatory effects of a novel soluble cyclodextrin formulation of nebulized budesonide in patients with mild to moderate asthma. Ann Allergy Asthma Immunol (2009) 0.76
The effects of butterbur on the histamine and allergen cutaneous response. Ann Allergy Asthma Immunol (2004) 0.76